Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer

Open Access 25-04-2024 | Pancreatectomy | Review

Surgical aspects related to hereditary pancreatic cancer

Authors: Elisabeth Maurer, Detlef K. Bartsch

Published in: Familial Cancer

Login to get access

Abstract

The goal of surveillance programs for individuals at risk (IAR) from familial pancreatic cancer (FPC) families or families with other inherited tumor syndromes predisposing to the development of pancreatic adenocarcinoma (PDAC), such as hereditary pancreatitis or Peutz-Jeghers syndrome, is the dectection and consecutive curative resection of early PDAC or even better its high-grade precursor lesions. Although the indication for surgery is quite established, the extent of surgery is not well defined due to the lack of evidence-based data. In addition, multiple factors have to be taken into account to determine an optimal personalized surgical strategy. This holds especially true since pancreatic surgery is associated with a relatively high morbidity and might impair the quality of life significantly. In this article the surgical aspects in the setting of hereditary PDAC are discussed.
Literature
1.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M (2020) International Cancer of the pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the pancreas Screening (CAPS) Consortium. Gut 69(1):7–17CrossRefPubMed
2.
Aslanian HR, Lee JH, Canto MI (2020) AGA clinical practice update on Pancreas Cancer Screening in High-Risk individuals: Expert Review. Gastroenterology 159(1):358–362CrossRefPubMed
3.
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M (2013) International Cancer of pancreas Screening (CAPS) Consortium. International Cancer of the pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347CrossRefPubMed
4.
Seufferlein T et al Konsultationsfassung S3-Leitlinie Exokrines Pankreaskarzinom Version 3.01-August 2023; AWMF-Registernummer: 032-010OL
5.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV (2021) Pancreatic adenocarcinoma, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 19(4):439–457CrossRefPubMed
6.
European Study Group on Cystic Tumours of the Pancreas (2018) European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67(5):789–804CrossRef
7.
Potjer TP, Schot I, Langer P et al (2013) Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 19:442–449CrossRefPubMed
8.
Bartsch DK, Slater EP, Carrato A, Ibrahim IS, Guillen-Ponce C, Vasen HF, Matthäi E, Earl J, Jendryschek FS, Figiel J, Steinkamp M, Ramaswamy A, Vázquez-Sequeiros E, Muñoz-Beltran M, Montans J, Mocci E, Bonsing BA, Wasser M, Klöppel G, Langer P, Fendrich V, Gress TM (2016) Refinement of screening for familial pancreatic cancer. Gut 65(8):1314–1321CrossRefPubMed
9.
Konings IC, Harinck F, Poley JW et al (2017) Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer. Pancreas 46:28–34CrossRefPubMed
10.
Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, Konings ICAW, Paiella S, Earl J, Fockens P, Gress TM, Ausems MGEM, Poley JW, Thosani NC, Half E, Lachter J, Stoffel EM, Kwon RS, Stoita A, Kastrinos F, Lucas AL, Syngal S, Brand RE, Chak A, Carrato A, Vleggaar FP, Bartsch DK, van Hooft JE, Cahen DL, Canto MI, Bruno MJ, International Cancer of the Pancreas Screening Consortium (2022) Timeline of Development of Pancreatic Cancer and implications for successful early detection in high-risk individuals. Gastroenterology 162(3):772–785e4CrossRefPubMed
11.
Dbouk M, Brewer Gutierrez OI, Lennon AM et al (2021) Guidelines on management of pancreatic cysts detected in high-risk individuals: an evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the pancreas Screening (CAPS) consortium statements. Pancreatology 21:613–621CrossRefPubMed
12.
Bartsch DK, Dietzel K, Bargello M, Matthaei E, Kloeppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, Langer P (2013) Multiple small imaging branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 12(1):89–96CrossRefPubMed
13.
Zureikat AH, Beane JD, Zenati MS, Al Abbas AI, Boone BA, Moser AJ, Bartlett DL, Hogg ME (2021) Zeh HJ 3rd. 500 minimally invasive robotic pancreatoduodenectomies: one decade of optimizing performance. Ann Surg 273(5):966–972CrossRefPubMed
14.
van der Heijde N, Vissers FL, Manzoni A, Zimmitti G, Balsells J, Berrevoet F, Bjornsson B, van den Boezem P, Boggi U, Bratlie SO, Burdio F, Coratti A, D’Hondt M, Del Pozo CD, Dokmak S, Fara R, Can MF, Festen S, Forgione A, Fristrup C, Gaujoux S, Groot Koerkamp B, Hackert T, Khatkov IE, Keck T, Seppänen H, Lips D, Luyer M, Pittau G, Maglione M, Molenaar IQ, Pessaux P, Roeyen G, Saint-Marc O, Cabus SS, van Santvoort H, van der Schelling G, Serradilla-Martin M, Souche FR, Suarez Muñoz MÁ, Marino MV, Besselink MG, Abu Hilal M (2023) Use and outcome of minimally invasive pancreatic surgery in the European E-MIPS registry. 25(4):400–408 HPB (Oxford). European Consortium on Minimally Invasive Pancreatic Surgery
15.
Müller PC, Breuer E, Nickel F, Zani S Jr, Kauffmann E, De Franco L, Tschuor C, Krohn PS, Burgdorf SK, Jonas JP, Oberkofler CE, Petrowsky H, Saint-Marc O, Seelen L, Molenaar IQ, Wellner U, Keck T, Coratti A, van Dam JL, de Wilde R, Koerkamp BG, Valle V, Giulianotti P, Ghabi E, Moskal D, Lavu H, Vrochides D, Martinie J, Yeo C, Sánchez-Velázquez P, Ielpo B, Ajay PS, Shah MM, Kooby DA, Gao S, Hao J, He J, Boggi U, Hackert T, Allen P, Borel-Rinkes IHM, Clavien PA (2023) Robotic distal pancreatectomy: a Novel Standard of Care? Benchmark values for Surgical outcomes from 16 International Expert centers. Ann Surg 278(2):253–259CrossRefPubMed
16.
Matthaei H, Hong SM, Mayo SC et al (2011) Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol 18:3493–3499CrossRefPubMedPubMedCentral
17.
Maurer E, Lehman B, Matthäi E, Denzer U, Figiel J, Jesinghaus M, Slater EP, Stefenelli U, Gress TM, Bartsch DK Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic cancer families. JCO.23.01400R1 under review.
18.
Bartsch DK, Matthäi E, Mintziras I, Bauer C, Figiel J, Sina-Boemers M, Gress TM, Langer P, Slater EP (2021) The German National Case Collection for familial pancreatic carcinoma (FaPaCa)—Knowledge gained in 20 years. Dtsch Arztebl Int 118(10):163–168PubMed
19.
Scholten L, Stoop TF, Del Chiaro M, Busch OR, van Eijck C, Molenaar IQ, de Vries JH, Besselink MG (2019) Dutch pancreatic Cancer Group. Systematic review of functional outcome and quality of life after total pancreatectomy. Br J Surg 106(13):1735–1746CrossRefPubMed
20.
Langer P, Rothmund M, Bartsch DK (2006) Prophylaktische Chirurgie Des Pankreas [Prophylactic pancreas surgery]. Chirurg 77(1):25–32CrossRefPubMed
21.
Scholten L, Latenstein AE, Aalfs CM, Bruno MJ, Busch OR, Bonsing BA, Koerkamp BG, Molenaar IQ, Ubbink DT, van Hooft JE, Fockens P, Glas J, DeVries JH, Besselink MG, Dutch Pancreatic Cancer Group (2020) Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. United Eur Gastroenterol J 8(8):865–877CrossRef
22.
Bennett C, Suguitan M, Abad J, Chawla A (2022) Identification of high-risk germline variants for the development of pancreatic cancer: common characteristics and potential guidance to screening guidelines. Pancreatology 22(6):719–729CrossRefPubMed
23.
Le Cosquer G, Maulat C, Bournet B, Cordelier P, Buscail E, Buscail L (2023) Pancreatic Cancer in chronic pancreatitis: Pathogenesis and Diagnostic Approach. Cancers (Basel) 15(3):761CrossRefPubMed
24.
25.
Najarian JS, Sutherland DE, Baumgartner D, Burke B, Rynasiewicz JJ, Matas AJ, Goetz FC (1980) Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg 192(4):526–542CrossRefPubMedPubMedCentral
26.
Nathan JD, Yang Y, Eaton A, Witkowski P, Wijkstrom M, Walsh M, Trikudanathan G, Singh VK, Schwarzenberg SJ, Pruett TL, Posselt A, Naziruddin B, Mokshagundam SP, Morgan K, Lara LF, Kirchner V, He J, Gardner TB, Freeman ML, Ellery K, Conwell DL, Chinnakotla S, Beilman GJ, Ahmad S, Abu-El-Haija M, Hodges JS, Bellin MD (2022) Surgical approach and short-term outcomes in adults and children undergoing total pancreatectomy with islet autotransplantation: a report from the prospective observational study of TPIAT. Pancreatology 22(1):1–8CrossRefPubMed
27.
Ludwig B, Reichel A, Steffen A, Zimerman B, Schally AV, Block NL, Colton CK, Ludwig S, Kersting S, Bonifacio E, Solimena M, Gendler Z, Rotem A, Barkai U, Bornstein SR (2013) Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A 110(47):19054–19058CrossRefPubMedPubMedCentral
28.
Bellin MD, Freeman ML, Gelrud A, Slivka A, Clavel A, Humar A, Schwarzenberg SJ, Lowe ME, Rickels M, Whitcomb DC et al (2014) Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology 14:27–35CrossRefPubMed
29.
Balzano G, Maffi P, Nano R, Mercalli A, Melzi R, Aleotti F, Zerbi A, De Cobelli F, Gavazzi F, Magistretti P et al (2016) Autologous islet transplantation in patients requiring pancreatectomy: a broader spectrum of indications beyond chronic pancreatitis. Am J Transpl 16:1812–1826CrossRef
30.
31.
Charpentier KP, Brentnall TA, Bronner MP, Byrd D, Marsh C (2004) A new indication for pancreas transplantation: high grade pancreatic dysplasia. Clin Transpl 18(1):105–107CrossRef
32.
Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R, Signoretti M, Crippa S, Carrara S, Frigerio I, Bassi C, Falconi M, Iannicelli E, Giardino A, Mannucci A, Laghi A, Laghi L, Frulloni L, Zerbi A (2019) Results of First-Round of Surveillance in individuals at high-risk of pancreatic Cancer from the AISP (Italian Association for the study of the Pancreas) Registry. Am J Gastroenterol 114(4):665–670CrossRefPubMed
33.
Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen, Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK (2016) Benefit of Surveillance for Pancreatic Cancer in High-Risk individuals: outcome of long-term prospective Follow-Up studies from three European Expert centers. J Clin Oncol 34(17):2010–2019CrossRefPubMed
34.
Canto MI, Kerdsirichairat T, Yeo CJ, Hruban RH, Shin EJ, Almario JA, Blackford A, Ford M, Klein AP, Javed AA, Lennon AM, Zaheer A, Kamel IR, Fishman EK, Burkhart R, He J, Makary M, Weiss MJ, Schulick RD, Goggins MG, Wolfgang CL (2020) Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic Cancer. J Gastrointest Surg 24(5):1101–1110CrossRefPubMed
35.
Paiella S, Secchettin E, Lionetto G, Archibugi L, Azzolina D, Casciani F, Simeone DM, Overbeek KA, Goggins M, Farrell J, Ponz de Leon Pisani R, Tridenti M, Corciulo MA, Malleo G, Arcidiacono PG, Falconi M, Gregori D, Bassi C, Salvia R, Capurso G (2023 Sep) Surveillance of individuals at high risk of developing pancreatic Cancer: a prevalence meta-analysis to Estimate the rate of low-yield surgery. Ann Surg 8. https://​doi.​org/​10.​1097/​SLA.​0000000000006094​Epub ahead of print
36.
Paiella S, Capurso G, Carrara S, Secchettin E, Casciani F, Frigerio I, Zerbi A, Archibugi L, Bonifacio C, Malleo G, Cavestro GM, Barile M, Larghi A, Assisi D, Fantin A, Milanetto AC, Fabbri C, Casadei R, Donato G, Sassatelli R, De Marchi G, Di Matteo FM, Arcangeli V, Panzuto F, Puzzono M, Buono AD, Pezzilli R, Salvia R, Rizzatti G, Casadio M, Franco M, Butturini G, Pasquali C, Coluccio C, Ricci C, Cicchese N, Sereni G, de Pretis N, Stigliano S, Rudnas B, Marasco M, Lionetto G, Arcidiacono PG, Terrin M, Crovetto A, Mannucci A, Laghi L, Bassi C, Falconi M (2023 Oct) Outcomes of a 3-year prospective surveillance in individuals at high-risk for pancreatic cancer. Am J Gastroenterol 3. https://​doi.​org/​10.​14309/​ajg.​0000000000002546​Epub ahead of print
37.
Lu C, Xu CF, Wan XY et al (2015) Screening for pancreatic cancer in familial high-risk individuals: a systematic review. World J Gastroenterol 21:8678–8686CrossRefPubMedPubMedCentral
38.
McGuigan A, Kelly P, Turkington RC et al (2018) Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24:4846–4861CrossRefPubMedPubMedCentral
39.
40.
Klatte DCF, Boekestijn B, Wasser MNJM, Feshtali Shahbazi S, Ibrahim IS, Mieog JSD, Luelmo SAC, Morreau H, Potjer TP, Inderson A, Boonstra JJ, Dekker FW, Vasen HFA, van Hooft JE, Bonsing BA, van Leerdam ME (2022) Pancreatic Cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-Year prospective Follow-Up. J Clin Oncol 40(28):3267–3277CrossRefPubMed
41.
Corral JE, Mareth KF, Riegert-Johnson DL et al (2019) Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic Cancer: a Meta-analysis of Cohort studies. Clin Gastroenterol Hepatol 17:41–53CrossRefPubMed
42.
Overbeek KA, Cahen DL, Kamps A, Konings ICAW, Harinck F, Kuenen MA, Koerkamp BG, Besselink MG, van Eijck CH, Wagner A, Ausems MGE, van der Vlugt M, Fockens P, Vleggaar FP, Poley JW, van Hooft JE, Bleiker EMA, Bruno MJ (2020) Dutch familial pancreatic Cancer Surveillance Study Group. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Fam Cancer 19(3):247–258CrossRefPubMedPubMedCentral
Metadata
Title
Surgical aspects related to hereditary pancreatic cancer
Authors
Elisabeth Maurer
Detlef K. Bartsch
Publication date
25-04-2024
Publisher
Springer Netherlands
Published in
Familial Cancer
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-024-00384-1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits